<DOC>
	<DOC>NCT00051688</DOC>
	<brief_summary>The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.</brief_summary>
	<brief_title>Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Tezacitabine</mesh_term>
	<criteria>Patients with metastatic colorectal adenocarcinoma who have failed one prior course of chemotherapy. Patients must have at least one measurable tumor. Patients may not have received prior treatment with oxaliplatin.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>